Implications of the Updates to the Pharmaceutical Research and Manufacturers of America Code

The Pharmaceutical Research and Manufacturers of America, a trade group that represents research-based pharmaceutical and biotechnology companies in the United States, has released a new version of its Code on Interactions with Health Care Professionals. The new code – released in August 2021, perhaps in response to the Special Fraud Alert issued by the Office of Inspector General of the U.S. Department of Health and Human Services in November 2020 – has companies taking note of more stringent recommendations regarding sponsored speaker programs. The Anti‑Corruption Report recently spoke with Michelle Mc Guinness, president and principal of Pharmaceutical Compliance Partners and vice president of regulatory strategy and submissions at NGT Biopharmaceutical Consultants, about the drivers behind this shift and the practical implications for companies looking to integrate the new guidance into their programs, policies and practices. See “Lessons on Compliant Speaker Programs From the OIG’s Life Sciences Fraud Alert” (May 21, 2021).

To read the full article

Continue reading your article with an ACR subscription.